Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Mesoblast Limited ( (AU:MSB) ) has issued an update.
Mesoblast Limited has notified the market that 3,276,056 new ordinary fully paid shares have been issued following the exercise or conversion of previously unquoted options or other convertible securities. The issuance, effective March 31, 2026, marginally increases the company’s share capital and may modestly dilute existing holdings while providing additional equity funding flexibility.
The move reflects the crystallization of unquoted incentive or financing-related instruments into ordinary equity, signaling that prior option or conversion conditions have been met. While the scale is limited relative to Mesoblast’s overall capitalization, the conversion underscores ongoing engagement with equity-based funding and incentive structures as the company advances its business strategy.
The most recent analyst rating on (AU:MSB) stock is a Buy with a A$3.23 price target. To see the full list of analyst forecasts on Mesoblast Limited stock, see the AU:MSB Stock Forecast page.
More about Mesoblast Limited
Mesoblast Limited is an Australian biotechnology company listed on the ASX under the code MSB. The company focuses on developing and commercializing cellular medicines, particularly regenerative therapies, targeting serious and chronic conditions in global healthcare markets.
Average Trading Volume: 4,151,861
Technical Sentiment Signal: Sell
Current Market Cap: A$2.8B
See more data about MSB stock on TipRanks’ Stock Analysis page.